San Donato, Italy Clinical Trials

A Attilio Olivieri

Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML

MRD driven study. Addition of gemtuzumab to conventional chemotherapy to reduce MRD of patients with favorable/intermediate-risk AML. Post-consolidation assessment of MRD. Role of a post-SCT maintenance with glasdegib.

Medtronic Cardiac Surgery PMCF Registry

This registry is being conducted to support ongoing post-market surveillance activities.